Evidence map›Paper›PMID 41772709›Full record

ArticleTranslational neurodegeneration2026

SSEA3 and CD105 positivity are associated with the treatment potency of human neural crest-derived nasal turbinate stem cells for Alzheimer's disease.

Jung Yeon Lim, Jung Eun Lee, Minho Lee, Haewon Shim, Sang In Park, Soon A Park, Sin-Soo Jeun, Sheng-Min Wang, Sunghwan Kim, Seung Ho Yang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational neurodegeneration, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jung Yeon Lim *Department of Otolaryngology-Head and Neck Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero Seocho-gu, Seoul, 09591, Republic of Korea.
Jung Eun Lee *Department of Neurosurgery, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, 93 Jungbu-daero, paldal-gu, Suwon-si, Seoul, 16247, Republic of Korea.
Minho Lee *Department of Life Science, Dongguk University, 30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea.
Haewon ShimDepartment of Life Science, Dongguk University, 30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea.
Sang In ParkInstitute of Catholic Integrative Medicine (ICIM), Incheon St. Mary's Hospital, The Catholic University of Korea, 56 Dongsu-ro, Bupyeong-dong, Bupyeonggu, Incheon, 21431, Republic of Korea.
Soon A ParkDepartment of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero Seocho-gu, Seoul, 09591, Republic of Korea.
Sin-Soo JeunDepartment of Neurosurgery, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero Seocho-gu, Seoul, 09591, Republic of Korea.
Sheng-Min WangDepartment of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, 10 63-ro Yeongdeungpo-gu , Seoul, 07345, Republic of Korea.
Sunghwan KimDepartment of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, 10 63-ro Yeongdeungpo-gu , Seoul, 07345, Republic of Korea.
Seung Ho YangDepartment of Neurosurgery, College of Medicine, St. Vincent's Hospital, The Catholic University of Korea, 93 Jungbu-daero, paldal-gu, Suwon-si, Seoul, 16247, Republic of Korea. 72ysh@catholic.ac.kr.
Hyun Kook LimDepartment of Psychiatry, Yeouido St. Mary's Hospital, The Catholic University of Korea, 10 63-ro Yeongdeungpo-gu , Seoul, 07345, Republic of Korea. drblues@catholic.ac.kr.
Sung Won KimDepartment of Otolaryngology-Head and Neck Surgery, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, 222 Banpo-daero Seocho-gu, Seoul, 09591, Republic of Korea. kswent@catholic.ac.kr.

Funding

Korea Dementia Research Center HU22C0070Ministry of Food and Drug Safety RS-2024-00397128National Research Foundation of Korea 2021M3F7A1083232National Research Foundation of Korea 2021R1C1C2010469National Research Foundation of Korea 2022R1A2C1007556
6 · The paper itself

Abstract

backgroundStem cells have the potential to treat Alzheimer's disease (AD), but clinical outcomes are unpredictable due to inter-donor differences in stem cell properties. This study aimed to determine whether the pluripotency marker SSEA3 and the mesenchymal marker CD105 positivity are associated with the therapeutic efficacy of human neural crest-derived nasal turbinate stem cells (NTSCs) for AD.

methodsThe therapeutic effects of NTSCs obtained from different donors, with varying percentages of SSEA3

resultsNTSCs from different donors improved cognitive function and AD-related neuropathology to varying degrees, depending on the percentage of SSEA3

conclusionsOur findings suggest that SSEA3/CD105 positivity is a potential marker of NTSC therapeutic efficacy for the treatment of AD. Future studies should focus on enhancing the therapeutic potential of SSEA3

Indexed as

Alzheimer DiseaseEndoglinNeural CrestStage-Specific Embryonic AntigensStem Cell TransplantationAnimalsFemaleHumansMaleMiceMice, TransgenicEndoglinENG protein, humanstage-specific embryonic antigen-4Stage-Specific Embryonic AntigensAlzheimer’s diseaseCognitive functionHuman neural crest-derived nasal turbinate stem cellsNeuroinflammationSSEA3+/CD105+ cellsStem cell therapy

Identifiers

PMID41772709
PMCPMC12955099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.